We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00427791
First Posted: January 29, 2007
Last Update Posted: May 9, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
Results First Submitted: January 19, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Leukemia
Interventions: Drug: Etoposide
Radiation: Total Body Irradiation
Drug: Rituximab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment Period: July 05, 2005 to August 08, 2008. All participants were enrolled at UT MD Anderson Cancer Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Etoposide + Total Body Irradiation + Rituximab Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
Etoposide + Total Body Irradiation Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days

Participant Flow:   Overall Study
    Etoposide + Total Body Irradiation + Rituximab   Etoposide + Total Body Irradiation
STARTED   10   13 
COMPLETED   10   13 
NOT COMPLETED   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Etoposide + Total Body Irradiation + Rituximab Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
Etoposide + Total Body Irradiation Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
Total Total of all reporting groups

Baseline Measures
   Etoposide + Total Body Irradiation + Rituximab   Etoposide + Total Body Irradiation   Total 
Overall Participants Analyzed 
[Units: Participants]
 10   13   23 
Age 
[Units: Participants]
     
<=18 years   0   1   1 
Between 18 and 65 years   10   12   22 
>=65 years   0   0   0 
Gender 
[Units: Participants]
     
Female   3   4   7 
Male   7   9   16 
Region of Enrollment 
[Units: Participants]
     
United States   10   13   23 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Progression-free Survival (PFS)   [ Time Frame: 2 Years post transplant or until disease progression or death ]

2.  Secondary:   Number of Participants With Incidence of Acute Graft Versus Host Disease During First 100 Days   [ Time Frame: During the first 100 days following transplant ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. Partow Kebriaei, Associate Professor
Organization: UT MD Anderson Cancer Center
phone: 713-792-2648
e-mail: ytdinh@mdanderson.org



Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00427791     History of Changes
Other Study ID Numbers: 2004-0989
First Submitted: January 25, 2007
First Posted: January 29, 2007
Results First Submitted: January 19, 2012
Results First Posted: May 7, 2012
Last Update Posted: May 9, 2016